Kazia Therapeutics (KZIA) Net Income towards Common Stockholders (2009 - 2017)

Kazia Therapeutics' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at -$8.2 million for Q2 2017.

• Quarterly Net Income towards Common Stockholders rose 10.04% year-over-year to -$8.2 million in Q2 2017, while the trailing twelve-month figure through Dec 2018 was -$8.2 million (up 59.93% YoY) and the FY2025 annual result came in at -$13.3 million, up 24.13% from the prior year.
• Net Income towards Common Stockholders was -$8.2 million for Q2 2017 at Kazia Therapeutics, down from -$3.1 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$3.1 million in Q4 2016 and bottomed at -$3055.3 billion in Q4 2013.
• A 5-year average of -$509.2 billion and a median of -$7.3 million in 2014 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2013 — Net Income towards Common Stockholders sank 200037442.72% — and 2014, when it surged 100.0%.
• Kazia Therapeutics' Net Income towards Common Stockholders stood at -$3055.3 billion in 2013, then surged by 100.0% to -$6.5 million in 2014, then increased by 18.79% to -$5.3 million in 2015, then jumped by 40.33% to -$3.1 million in 2016, then slumped by 160.23% to -$8.2 million in 2017.
• Business Quant data shows KZIA's Net Income towards Common Stockholders at -$8.2 million in Q2 2017, -$3.1 million in Q4 2016, and -$9.1 million in Q2 2016.